6489 LOGO20THELANSIS 10

According to a literature survey, The American Journal of Respiratory and Critical Care Medicine estimates that European rates of incidence for COPD are between 0.185% and 0.288%. Overall, however, there are few incidence numbers published for COPD. Since the condition is chronic in nature without a clear onset, it is difficult to quantify new (i.e., incident) cases. Also, individuals often ignore early symptoms of COPD until their condition is in a late stage.

Read more:-Chronic Obstructive Pulmonary Disease (COPD) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Chronic-Obstructive-Pulmonary-Disease-COPD-forecast

Comprehensive insight on patient segmentation based on age, sex, Classification, and severity of COPD (Mild, Moderate, Severe & Very severe), Stages (Stage I, II, III, IV), and classification based on: forced expiratory volume & forced vital capacity, COPD Exacerbation (No respiratory failure, ARF – Nonlife threatening, ARF – Non-life threatening), Signs & Symptoms, Clinical Manifestations, Treatment types has been provided into the epidemiology section of the COPD and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

CI IMAGE

In terms of pharmacologic therapies, there are many drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, AstraZeneca, Theravance Biopharma, Chiesi Farmaceutici, Novartis, Verona Pharma, Sanofi/ Regeneron, GlaxoSmithKline, Inmunotek, Pearl Therapeutics, Astellas Pharma, MedImmune LLC, Janssen Research building their assets under advance stage of development targeting COPD. Apart from the above companies like Alexza Pharmaceuticals, Regent Therapeutics, etc. are targeting the COPD market with their early phases of development considering the current potential and upcoming market opportunities.

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Sturge-Weber syndrome (SWS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Painful Diabetic Peripheral Neuropathy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Hemophagocytic Lymphohistiocytosis (HLH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Acute Hepatic Porphyria – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Hidradenitis Suppurativa (HS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

[email protected]

[email protected]

Tags: Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease (COPD) market outlook report, Chronic Obstructive Pulmonary Disease (COPD) competitive landscape, Chronic Obstructive Pulmonary Disease (COPD) market forecast